{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fusion&page=29",
    "query": {
      "intervention": "Fusion",
      "page": 29
    },
    "page_size": 10
  },
  "pagination": {
    "page": 29,
    "page_size": 10,
    "total_count": 1228,
    "total_pages": 123,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fusion&page=30&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fusion&page=28&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T06:15:12.676Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02262455",
      "title": "Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Endometrial Cancer",
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "STM 434",
          "type": "DRUG"
        },
        {
          "name": "Liposomal doxorubicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Santa Maria Biotherapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2014-10",
      "completion_date": "2017-01-13",
      "has_results": false,
      "last_update_posted_date": "2017-02-13",
      "last_synced_at": "2026-10-24T06:15:12.676Z",
      "location_count": 4,
      "location_summary": "Boston, Massachusetts • New York, New York • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02262455"
    },
    {
      "nct_id": "NCT03699891",
      "title": "Evaluation of the Fortilink IBF System With TETRAfuse Technology",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cervical and Lumbar Fusion"
      ],
      "interventions": [
        {
          "name": "Fortilink IBF System with TETRAfuse Technology",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "RTI Surgical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 119,
      "start_date": "2018-11-06",
      "completion_date": "2019-01-15",
      "has_results": false,
      "last_update_posted_date": "2019-10-02",
      "last_synced_at": "2026-10-24T06:15:12.676Z",
      "location_count": 5,
      "location_summary": "Sherman Oaks, California • Lone Tree, Colorado • Boca Raton, Florida + 2 more",
      "locations": [
        {
          "city": "Sherman Oaks",
          "state": "California"
        },
        {
          "city": "Lone Tree",
          "state": "Colorado"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Delray Beach",
          "state": "Florida"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03699891"
    },
    {
      "nct_id": "NCT04317781",
      "title": "Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Blastic Plasmacytoid Dendritic Cell Neoplasm"
      ],
      "interventions": [
        {
          "name": "Tagraxofusp-erzs",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2020-03-27",
      "completion_date": "2023-07-11",
      "has_results": true,
      "last_update_posted_date": "2024-07-31",
      "last_synced_at": "2026-10-24T06:15:12.676Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04317781"
    },
    {
      "nct_id": "NCT02808585",
      "title": "Study to Assess the Safety, Tolerability and PK/PD After 4 Weekly SC Injections of PB1046 in Subjects With Stable HFrEF",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "PB1046 Injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PhaseBio Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2016-06",
      "completion_date": "2017-12-06",
      "has_results": true,
      "last_update_posted_date": "2022-07-14",
      "last_synced_at": "2026-10-24T06:15:12.676Z",
      "location_count": 5,
      "location_summary": "Anniston, Alabama • Peoria, Arizona • Daytona Beach, Florida + 2 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "McKinney",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02808585"
    },
    {
      "nct_id": "NCT03066661",
      "title": "Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Cancers With NTRK, ROS1, or ALK Gene Fusions"
      ],
      "interventions": [
        {
          "name": "Entrectinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2019-04-26",
      "last_synced_at": "2026-10-24T06:15:12.676Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03066661"
    },
    {
      "nct_id": "NCT04440735",
      "title": "A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Non Small Cell Lung Cancer",
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "DSP107",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Atezolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Kahr Medical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 125,
      "start_date": "2020-10-07",
      "completion_date": "2025-09",
      "has_results": false,
      "last_update_posted_date": "2025-01-09",
      "last_synced_at": "2026-10-24T06:15:12.676Z",
      "location_count": 7,
      "location_summary": "La Jolla, California • Aurora, Colorado • Lake Mary, Florida + 4 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Lake Mary",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04440735"
    },
    {
      "nct_id": "NCT02576496",
      "title": "Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hematological Malignancies",
        "Multiple Myeloma",
        "Hodgkin's Lymphoma",
        "Cutaneous T Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Tinostamustine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mundipharma Research Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 106,
      "start_date": "2016-04-14",
      "completion_date": "2023-11-21",
      "has_results": false,
      "last_update_posted_date": "2024-07-25",
      "last_synced_at": "2026-10-24T06:15:12.676Z",
      "location_count": 4,
      "location_summary": "Phoenix, Arizona • Jacksonville, Florida • New York, New York + 1 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02576496"
    },
    {
      "nct_id": "NCT00996073",
      "title": "Safety and Preliminary Efficacy Study of NeoFuse in Subjects Requiring Lumbar Interbody Fusion",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Degenerative Disc Disease",
        "Degenerative Spondylolisthesis",
        "Spinal Stenosis"
      ],
      "interventions": [
        {
          "name": "Lumbar Interbody Fusion with Autograft",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lumbar Interbody Fusion with NeoFuse",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Mesoblast, Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 24,
      "start_date": "2009-09",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2020-06-29",
      "last_synced_at": "2026-10-24T06:15:12.676Z",
      "location_count": 5,
      "location_summary": "Santa Monica, California • Greenwood Village, Colorado • Loveland, Colorado + 2 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Greenwood Village",
          "state": "Colorado"
        },
        {
          "city": "Loveland",
          "state": "Colorado"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00996073"
    },
    {
      "nct_id": "NCT07359820",
      "title": "A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "FGFR2 Gene Fusion/Rearrangement",
        "Other Solid Tumors, Adult"
      ],
      "interventions": [
        {
          "name": "Lirafugratinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Elevar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2026-06-04",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-10-24T06:15:12.676Z",
      "location_count": 8,
      "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Tampa, Florida + 5 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07359820"
    },
    {
      "nct_id": "NCT04019288",
      "title": "AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Platinum-Resistant Fallopian Tube Carcinoma",
        "Platinum-Resistant Ovarian Carcinoma",
        "Platinum-Resistant Primary Peritoneal Carcinoma",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma",
        "Refractory Fallopian Tube Carcinoma",
        "Refractory Ovarian Carcinoma",
        "Refractory Primary Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Batiraxcept",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 12,
      "start_date": "2019-12-03",
      "completion_date": "2024-10-24",
      "has_results": true,
      "last_update_posted_date": "2025-06-11",
      "last_synced_at": "2026-10-24T06:15:12.676Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04019288"
    }
  ]
}